An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Surmodics to Host Virtual Annual Meeting of Shareholders
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Surmodics, Inc. (Nasdaq: SRDX) will conduct its Annual Meeting of Shareholders on February 10 at 4 p.m. CT as a virtual event. Board chair Sue Knight and CEO Gary Maharaj will discuss key business updates and strategic initiatives. Participants can join the meeting via www.virtualshareholdermeeting.com/SRDX22. A replay will be available until February 10, 2023. Surmodics focuses on advancing medical device technologies and diagnostics.
Positive
None.
Negative
None.
Virtual Meeting on February 10 at 4 p.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 10, at 4:00 p.m. CT (5:00 p.m. ET), as a virtual meeting. Sue Knight, board chair, will lead the meeting, and Gary Maharaj, chief executive officer, will provide a brief update on business and key strategic initiatives underway at the Company.
To attend the virtual meeting, go to www.virtualshareholdermeeting.com/SRDX22 at least five minutes prior to the start of the meeting to log in. A webcast replay of the Annual Meeting will be available until February 10, 2023.
About Surmodics, Inc.
Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission (“SEC”).